181,390 Shares in Catalyst Pharmaceuticals, Inc. $CPRX Bought by Systematic Financial Management LP

Key Points

• Systematic Financial Management LP purchased 181,390 shares of Catalyst Pharmaceuticals, Inc. for approximately $4.4 million, representing around 0.15% ownership of the company.
• Insider Preethi Sundaram sold 2,324 shares at an average price of $26.41, reducing their position by 5.16%, while corporate insiders own about 10.40% of the company's stock.
• Catalyst Pharmaceuticals has received mixed ratings from analysts, with a consensus "Buy" rating and an average price target of $33.20.

Systematic Financial Management LP bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 181,390 shares of the biopharmaceutical company's stock, valued at approximately $4,399,000. Systematic Financial Management LP owned about 0.15% of Catalyst Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CPRX. Park Square Financial Group LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $29,000. Sound Income Strategies LLC acquired a new stake in Catalyst Pharmaceuticals during the first quarter worth about $64,000. GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares in the last quarter. Quarry LP purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $104,000. Finally, PNC Financial Services Group Inc. raised its position in Catalyst Pharmaceuticals by 57.2% during the first quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock valued at $133,000 after acquiring an additional 2,002 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 2.5%

Shares of Catalyst Pharmaceuticals stock opened at $21.08 on Friday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.00 and a twelve month high of $26.58. The business has a 50-day moving average price of $21.29 and a 200 day moving average price of $22.60. The firm has a market cap of $2.58 billion, a PE ratio of 12.78, a P/E/G ratio of 0.86 and a beta of 0.70.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 2,324 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total value of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares in the company, valued at $1,127,205.21. The trade was a 5.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

CPRX has been the subject of several recent research reports. Wall Street Zen cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Zacks Research cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $33.20.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.